BSI-508 / Biosion - LARVOL DELTA

BSI-508, a novel bispecific fusion molecule targeting PD1 and CD47 for cancer immunotherapy (AACR 2023) - "BSI-508 demonstrated comparable activity to the parental anti-PD1 monoclonal antibody regarding PD1 binding and PD1/PDL1 blocking. It also exhibited comparable activity to the SIRPα-V2-ECD1-Fc fusion protein in CD47 binding and CD47/SIRPα blocking. BSI-508 was able to reverse PD1 mediated T-cell suppression and exhibited comparable bioactivity to the parental anti-PD1 antibody."

Oncology • CD47 • SIRPA

Biosion bispecific antibody therapies to be featured at the American Association for Cancer Research (AACR) annual meeting 2023 (PRNewswire) - "Biosion USA...announced the upcoming presentations of non-clinical data from its oncology pipeline, including BSI-507: anti-PD1ⅹanti-PVRIG bispecific antibody and BSI-508: anti-PD1ⅹanti-CD47 bispecific antibody, at the American Association for Cancer Research (AACR) Annual Meeting to be held from April 14 to 19, 2023."

Preclinical • Oncology